MARKET

ATRA

ATRA

Atara Biotherapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.38
+0.14
+0.86%
After Hours: 16.00 -0.38 -2.32% 18:09 09/21 EDT
OPEN
16.27
PREV CLOSE
16.24
HIGH
16.68
LOW
16.09
VOLUME
711.79K
TURNOVER
--
52 WEEK HIGH
28.20
52 WEEK LOW
11.81
MARKET CAP
1.39B
P/E (TTM)
-4.5074
1D
5D
1M
3M
1Y
5Y
10 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie
In this article, we will take a look at 10 pharmaceutical stocks to buy today according to Tiger Cub Billionaire Lee Ainslie. You can skip our detailed analysis of Lee Ainslie’s history, investment strategy, and hedge fund performance, and go directly to s...
Insider Monkey · 1d ago
Lymphoproliferative Disorder Treatment Market Emerging Trends, Market Research, And Comprehensive Insights 2028
Research Nester released a report titled "" which delivers detailed overview of the global lymphoproliferative disorder treatment market in terms of market segmentation by route of administration, drug class, application, distribution channel and by region...
AmericaNewsHour · 5d ago
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregat...
Business Wire · 09/03 20:01
Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
SOUTH SAN FRANCISCO, Calif., September 02, 2021--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune ...
Business Wire · 09/02 12:30
Copernicus Capital Management, LLC Buys Vertex Pharmaceuticals Inc, Atara Biotherapeutics Inc, ...
GuruFocus News · 08/23 22:38
Insider Trends: 90-Days of Insider Buying at Atara Biotherapeutics Eased Back with Share Disposition
MT Newswires · 08/19 19:48
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates
Zacks.com · 08/09 21:25
Atara Biotherapeutics Q2 EPS $(0.91) Misses $(0.89) Estimate, Sales $3.87M Beat $3.84M Estimate
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.89) by 2.25 percent. This is a 20.18 percent increase over losses of $(1.14) per share
Benzinga · 08/09 20:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATRA. Analyze the recent business situations of Atara Biotherapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATRA stock price target is 33.38 with a high estimate of 78.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 204
Institutional Holdings: 90.42M
% Owned: 106.68%
Shares Outstanding: 84.76M
TypeInstitutionsShares
Increased
46
6.02M
New
18
2.14M
Decreased
52
6.38M
Sold Out
24
2.37M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.43%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Director
Ronald Renaud
President/Chief Executive Officer/Director
Pascal Touchon
Chief Financial Officer/Senior Vice President
Utpal Koppikar
Chief Operating Officer/Executive Vice President
Joseph Newell
Executive Vice President
Jakob Dupont
Senior Vice President/General Counsel
K. Amar Murugan
Senior Vice President
Kristin Yarema
Lead Director/Independent Director
Carol Gallagher
Director
Ameet Mallik
Director
Maria Roncarolo
Independent Director
Roy Baynes
Independent Director
Eric Dobmeier
Independent Director
Matthew Fust
Independent Director
William Heiden
Independent Director
Beth Seidenberg
No Data
  • All
  • Financials
  • Insiders
More
About ATRA
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Webull offers kinds of Atara Biotherapeutics Inc stock information, including NASDAQ:ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.